RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Current MS therapies aim to modulate the immune system, but novel strategies are needed.
• Targeting ribosomal biogenesis via Polymerase-1 (POL1) transcription is a potential therapeutic avenue for MS.

Purpose of the Study:

• To develop and evaluate an oral compound, RAM-589.555, that inhibits POL1 transcription.
• To assess the compound's efficacy in suppressing ribosomal biogenesis and inducing apoptosis in lymphocytes.
• To determine the therapeutic potential of RAM-589.555 in ameliorating experimental autoimmune encephalomyelitis (EAE), an MS model.

Main Methods:

• Development of an oral POL1 inhibiting compound (RAM-589.555).
• In vitro and in vivo assessment of compound's effects on lymphocyte proliferation, viability, apoptosis, and POL1 pathway.
• Administration of RAM-589.555 in an experimental autoimmune encephalomyelitis (EAE) mouse model to evaluate disease suppression and amelioration.

Main Results:

• RAM-589.555 demonstrated high permeability and specificity for the POL1 pathway.
• The compound effectively inhibited lymphocyte proliferation and viability, inducing apoptosis in vitro and in vivo.
• Oral administration of RAM-589.555 blocked ribosomal RNA transcription and significantly suppressed and ameliorated EAE.

Conclusions:

• RAM-589.555 is a promising oral therapeutic agent targeting POL1 transcription for MS treatment.
• Suppression of ribosomal biogenesis by RAM-589.555 offers a novel mechanism for MS disease modification.
• The compound's ability to inhibit activated lymphocytes and ameliorate EAE supports its potential clinical utility in multiple sclerosis.